Valuation: Atossa Therapeutics, Inc.

Market Cap 20.75M 18.23M 16.95M 15.56M 29.23M 2B 29.68M 201M 78.64M 983M 77.91M 76.23M 3.4B P/E 2026 *
-0.56x
P/E 2027 * -0.7x
Enterprise Value 20.75M 18.23M 16.95M 15.56M 29.23M 2B 29.68M 201M 78.64M 983M 77.91M 76.23M 3.4B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-4.98%
1 week-6.02%
Current month+21.24%
1 month+33.71%
3 months-58.95%
6 months-77.24%
Current year-73.56%
1 week 2.32
Extreme 2.32
2.6
1 month 1.7
Extreme 1.7
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
67.2
10 years 1.7
Extreme 1.7
783
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2023-12-03
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 68 2014-03-02
Director/Board Member 74 2012-01-31
Date Insider Type Main position Quantity % Market Cap.
5/12/26 Free

Director

10,000 0.1161%
5/12/26
Ensisheim Partners LLC
OtherCompany 0 0%
5/12/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-4.98%-6.02%-81.90%-85.69% 20.75M
+1.07%-3.49%-3.25%+12.87% 46.35B
-0.50%+0.77%+404.03%+623.21% 40.13B
-0.14%+4.63%+10.12%+67.22% 36.33B
+1.04%+1.38%+4.12%-8.35% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.98%-2.49% - - 16.66B
+0.38%+12.80%+33.12%+145.64% 16.91B
+0.42%-5.52%+0.76%+8.50% 13.05B
-1.55%-1.37%-14.02%-30.89% 13.05B
Average -0.03%+1.00%+39.63%+85.26% 24.39B
Weighted average by Cap. +0.58%+0.77%+75.08%+135.82%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.84M -30.54M -28.03M -52.66M -3.6B -53.47M -363M -142M -1.77B -140M -137M -6.12B -39.31M -34.53M -32.11M -29.47M -55.36M -3.79B -56.22M -381M -149M -1.86B -148M -144M -6.44B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-07-24 US$2.340 -2.90% 16,036
26-07-23 US$2.410 -0.82% 37,171
26-07-22 US$2.430 +1.25% 26,603
26-07-21 US$2.400 -3.61% 106,083
26-07-20 US$2.490 0.00% 117,295
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.410USD
Average target price
22.00USD
Spread / Average Target
+812.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock